Interferon beta-1b for the treatment of primary progressive multiple sclerosis: Five-year clinical trial follow-up

Archives of Neurology

Volumn 68, Issue 11, 2011, Pages 1421-1427

  Tur, Carmen ^a   Montalban, Xavier ^a   Tintoré, Mar ^a   Nos, Carlos ^a   Río, Jordi ^a   Aymerich, Francesc Xavier ^b   Brieva, Luis ^a   Téllez, Nieves ^a   Perkal, Héctor ^a   Comabella, Manuel ^a   Galán, Ingrid ^a   Calle, David ^c   Sastre Garriga, Jaume ^a   Rovira, Alex ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Nuvisan Clinical Development Solutions   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE; PLACEBO;

ADULT; AGED; ARTICLE; BRAIN ATROPHY; CONTROLLED STUDY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE SCORE; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SPAIN; WHITE MATTER;

ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; NEUROPSYCHOLOGICAL TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 81355133371     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.241     Document Type: Article

References (39)

1. Kappos L; European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352(9139): 1491-1497.
2. Panitch H, Miller A, Paty D, Weinshenker B; North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63 (10):1788-1795. (Pubitemid 39532370)
3. Cohen JA, Cutter GR, Fischer JS, et al. IMPACT Investigators. Benefit of interferon β-1a on MSFC progression in secondary progressive MS. Neurology. 2002; 59(5):679-687.
4. Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis. Brain. 1997;120(pt 6):1085-1096. (Pubitemid 27259557)
5. Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol. 2000;47(6):831- 835.
6. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon β-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology. 2003;60(1):44-51. (Pubitemid 36070642)
7. Wolinsky JS, Narayana PA, O'Connor P, et al. PROMiSe Trial Study Group. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007; 61(1):14-24. (Pubitemid 46214240)
8. Montalban X, Sastre-Garriga J, Tintoré M, et al. A single-center, randomized, doubleblind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler. 2009;15(10):1195-1205.
9. Hawker K, O'Connor P, Freedman MS, et al. OLYMPUS Trial Group. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66(4):460-471.
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33(11):1444-1452. (Pubitemid 14237132)
11. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122(pt 5):871-882. (Pubitemid 29219261)
12. Río J, Rovira A, Tintoré M, et al. Relationship between MRI lesion activity and response to IFN-β in relapsing-remitting multiple sclerosis patients. Mult Scler. 2008;14(4):479-484. (Pubitemid 351943860)
13. Chiu AW, Richert N, Ehrmantraut M, et al. Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study. Arch Neurol. 2009;66(1):39-43.
14. Río J, Comabella M, Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol. 2009;5(10):553-560.
15. Bosma LV, Kragt JJ, Brieva L, et al. The search for responsive clinical endpoints in primary progressive multiple sclerosis. Mult Scler. 2009;15(6):715-720.
16. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67(2):206-207. (Pubitemid 17026064)
17. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
18. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121-1123. (Pubitemid 19246303)
19. Pollard WE, Bobbitt RA, Bergner M, Martin DP, Gilson BS. The Sickness Impact Profile: reliability of a health status measure. Med Care. 1976;14(2):146-155.
20. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BG, Burks JS. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology. 1996;46(1):12-18. (Pubitemid 26157582)
21. Bramanti P, Sessa E, Rifici C, et al. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b. Neurology. 1998;51(6):1720-1723.
22. Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology. 1999;53(8):1622-1627. (Pubitemid 29530329)
23. Knobler RL. Systemic interferon therapy of multiple sclerosis: the pros. Neurology. 1988;38(7)(suppl 2):58-61.
24. Jacobs LD, Beck RW, Simon JH, et al. CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000;343(13):898-904.
25. Fischer JS, Jak AJ, Kniker JE, Rudick RA, Cutter GR. Administration and Scoring Manual for the Multiple Sclerosis Functional Composite Measure (MSFC). 1st ed. London, England: UniTECH Communications; 1999.
26. Lechner-Scott J, Kappos L, Hofman M, et al. Can the Expanded Disability Status Scale be assessed by telephone? Mult Scler. 2003;9(2):154-159. (Pubitemid 36426990)
27. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis, I: frequency, patterns, and prediction. Neurology. 1991;41(5):685-691.
28. Plummer DL. A display and analysis tool for medical images [in Italian]. Riv Neuroradiol. 1992;5:489-495. (Pubitemid 23017719)
29. Aymerich FX, Sobrevilla P, Montseny E, Gili J, Rovira A. Fuzzy approach to lesion load measurements in T1-weighted images. Mult Scler. 2001;7(1) (suppl):87.
30. Aymerich FX, Sobrevilla P, Montseny E, Alonso J, Gili J, Rovira A. Application of an automatic segmentation algorithm to brain atrophy assessment in multiple sclerosis. Rev Neurol (Paris). 2000;156(S3):103-104.
31. Molyneux PD, Miller DH, Filippi M, et al. Visual analysis of serial T2-weighted MRI in multiple sclerosis: intra- and interobserver reproducibility. Neuroradiology. 1999;41(12):882-888. (Pubitemid 30000290)
32. Río J, Nos C, Tintoré M, et al. Defining the response to interferon-β in relapsingremitting multiple sclerosis patients. Ann Neurol. 2006;59(2):344-352. (Pubitemid 43202488)
33. Cohen JA, Cutter GR, Fischer JS, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol. 2001;58(6):961-967. (Pubitemid 32537471)
34. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol. 1995;37(1):30-40.
35. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol. 2004; 56(3):407-415. (Pubitemid 39166560)
36. Miller DH, Barkhof F, Frank JA, Parker GJM, Thompson AJ. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain. 2002;125(pt 8):1676-1695.
37. Sastre-Garriga J, Ingle GT, Rovaris M, et al. Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data. Neurology. 2005; 65(4):633-635. (Pubitemid 41170733)
38. Ingle GT, Sastre-Garriga J, Miller DH, Thompson AJ. Is inflammation important in early PPMS? a longitudinal MRI study. J Neurol Neurosurg Psychiatry. 2005;76(9):1255-1258. (Pubitemid 41208379)
39. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43-46. (Pubitemid 20255621)